Effect of Nonionic Surfactants (Dodecyl Maltoside and Polysorbate 20) on Prevention of Aggregation and Conformational Changes of Recombinant Human IFNβ_1b Induced by Light
Authors
Abstract
Liquid protein formulations are prone to form aggregates. The effect of nonionic surfactants such as Polysorbate 20 (PS 20) and n-Dodecyl β-D-maltoside (DDM) on the prevention of aggregation and conformational changes of recombinant human IFNβ-1b (rhIFN β_1b) was explored. Polysorbate has been used in formulations of protein pharmaceuticals. There have been concerns about using PS 20 due to its residual peroxide content which may negatively affect protein efficacy. n-Dodecyl β-D-maltoside has been of interest and shown to be highly effective in prevention of aggregation. Fresh bulk of rhIFN β_1b was formulated using DDM or different concentrations of PS 20. Formulations were exposed to light stress condition according to the ICH guideline of Q1b. The overall conformational integrity of individual samples was characterized by a combination of Circular dichroism (CD), Fluorescence spectroscopy and RP_HPLC techniques.
The CD spectrum depicting the conformational integrity of rhIFN β_1b showed 31.9% and 31.2% decreases in α-helix content of protein samples with 0.2% or 0.02% of PS20 compared to only18.2% of that containing 0.2% DDM. The RP-HPLC analysis also showed that the oxidized impurity in formulation containing DDM is less than those contain PS 20.
Complementary analysis of the liquid formulations using IFR and UV methods also was in compliance with the data obtained by CD.
Compared to PS 20, the sample of rhIFN β_1b formulation with DDM was more resistant to the destruction effect of light. Results were in accordance with previous studies and could suggest DDM as a reliable anti-aggregation surfactant in biopharmaceutical formulations.
Highlights
Acknowledgments
References
- 1.Frison-Norrie S, Sporns P. Investigating the molecular heterogeneity of polysorbate emulsifiers by MALDI-TOF MS. J. Agric. Food. Chem. 2001;49:3335-40. [PubMed ID: 11453772].
- 2.Donbrow M, Azaz E, Pillersdorf A. Autoxidation of polysorbates. J. Pharm. Sci. 1978;67:1676-81. [PubMed ID: 31449].
- 3.Donbrow M, Hamburger R, Azaz E. Surface tension and cloud point changes of polyoxyethylenic nonionic surfactants during autoxidation. J. Pharm. Pharmacol. 1975;27:160-6. [PubMed ID: 237997].
- 4.Bruce A, Kerwin BA. Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: structure and degradation pathways. J. Pharm. Sci. 2008;97:2924-35. [PubMed ID: 17973307].
- 5.Andrea H, Wolfgang F. Development of HSA-free formulations for a hydrophobic cytokine with improved stability. Eur. J. Pharm. Biopharm. 2008;68:169-82. [PubMed ID: 17574398].
- 6.Katdare AS, Chaubal MA. Excipient development for pharmaceutical, biotechnology and drug delivery systems. New York: Informa health care; 2006. p. 307-32.
- 7.Randolph TW, Jones LS. Surfactant-protein interactions Rational design of stable protein formulations. Pharm. Biotechnol. 2002;13:159-75. [PubMed ID: 11987751].
- 8.Bam NB, Randolph TW, Cleland JL. Stability of protein formulations: Investigation of surfactant effects by a novel EPR spectroscopic technique. Pharm. Res. 1995;12:2-11. [PubMed ID: 7724484].
- 9.Bam NB, Cleland JL, Yang J, Manning MC, Carpenter JF, Kelley RF, Randolph TW. Tween protects recombinant human growth hormone against agitation-induced damage via hydrophobic interactions. J. Pharm. Sci. 1998;12:1554-9.
- 10.Chou DK, Krishnamurthy R, Randolph TW, Carpenter JF, Manning MC. Effects of tween 20 and Tween 80 on the stability of albutropin during agitation. J. Pharm. Sci. 2005:20365.
- 11.Bam NB, Cleland JL, Randolph TW. Molten globule intermediate of recombinant human growth hormone: stabilization with surfactants. Biotechnol. Prog. 1996;12:801-9. [PubMed ID: 8983207].
- 12.Kreilgaard L, Jones LS, Randolph TW, Frokjaer S, Flink JM, Manning MC, Carpenter JF. Effect of Tween 20 on freeze-thawing- and agitation induced aggregation of recombinant human factor XIII. J. Pharm. Sci. 1998;87:1597-603. [PubMed ID: 10189273].
- 13.Horowitz PM. Kinetic control of protein folding by detergent micelle, liposomes, and chaperonins. Am. Chem. Soci. 1993;526:156-63.
- 14.Lee HJ, McAuley A, Schilke KF, McGuire J. Molecular origins of surfactant-mediated stabilization of protein drugs. Adv. Drug. Deliv. Rev. 2011;63:1160-71. [PubMed ID: 21763375].
- 15.Singh SR, O’Dell C, Zhang J, Hsieh M, Goldstein J, Liu J, Srivastava A. Effect of Polysorbate 80 quality on the photostability of a monoclonal antibody. AAPS Pharm. Sci. Tech. 2012;13:422-31.
- 16.Folahane O, Ayorinde FO, Slair V, Glain, James H, Jahnson JR, Lili W. Analysis of some commercial polysorbate formulations using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Rapid commun. Mass. Spectrom. 2000;14:2116-24. [PubMed ID: 11114018].
- 17.Brandner JD. The Composition of NF-defined emulsifiers: Sorbitan monolaurate, monopalmitate, monostearate, monooleate, polysorbate 20, polysorbate 40, polysorbate 60, and polysorbate 80. Drug. Dev. Ind. Pharm. 1998;24:1049-54. [PubMed ID: 9876559].
- 18.Donbrow M, Hamburger R, Azaz E, Pillersdorf A. Development of acidity in nonionic surfactants: formic and acetic acid. Analyst. 1978;103:400-2.
- 19.Ha E, Wang W, Wang YJ. Peroxide formation in polysorbate 80 and protein stability. J. Pharm. Sci. 2002;91:2252-64. [PubMed ID: 12226852].
- 20.Wasylaschuk WR, Harmon PA, Wagner G, Harman AB, Templeton AC, Xu H, Reed RA. Evaluation of hydroperoxides in common pharmaceutical excipients. J. Pharm. Sci. 2007;96:106-16. [PubMed ID: 16917844].
- 21.Sharma B. Immunogenicity of therapeutic proteins Part 1: impact of product handling. Biotechnol. Adv. 2007;25:310-7. [PubMed ID: 17336479].
- 22.Patro SY, Freund E, Chang BS. Protein formulation and fill-finish operations. Biotechnol.Annu. Rev. 2002;8:55-84. [PubMed ID: 12436915].
- 23.Lam XM, Yang JY, Cleland JL. Antioxidants for prevention of methionine oxidation in recombinant monoclonal antibody HER2. J. Pharm. Sci. 1997;86:1250-5. [PubMed ID: 9383735].
- 24.Gilli F, van Beers M, Marnetto F, Jiskoot W, Bertolotto A, Schellekens H. Development of a bioassay for quantification of neutralizing antibodies against human interferon-beta in mouse sera. J. Immunol. Methods. 2008;336:119-26. [PubMed ID: 18558408].
- 25.Creed D. The photophysics and photochemistry tryptophan and its simple derivatives photochem of the near-UV absorbing amino acids I. Photobiol. 1984;39:537-62.
- 26.Holt LA, Milligan B, Rivett DE, Stewart FHC. The photodecomposition of tryptophan peptide. Biochim. Biophys. Acta. 1977;499:131-8. [PubMed ID: 889893].
- 27.Van Beers MM, Sauerborn M, Gilli F, Brinks V, Schellekense H, Jiskoot W. Oxidized and aggregated recombinant human interferon beta is immunogenic in human interferon beta transgenic mice. Pharm. Res. 2011;28:2393-402. [PubMed ID: 21544687].
- 28.Rifkin RF, Maggio ET, Dike S, Kerr DA, Levy M. n-Dodecyl-beta-D-maltoside inhibits aggregation of human interferon β-1b and reduces its immunogenicity. J. Neuroimmun.Pharmacol. 2011;6:158-62.
- 29.Pillion DJ, Ahsan F, Arnold JJ, Balusubramanian BM, Piraner O, Meezan E. Synthetic long-chain alkyl maltosides and alkyl sucrose esters as enhancers of nasal insulin absorption. J. Pharm.Sci. 2002;91:1456-62. [PubMed ID: 12115845].
- 30.Pillion DJ, Atchison JA, Gargiulo C, Wang RX, Wang P, Meezan E. Insulin delivery in nosedrops: new formulations containing alkylglycosides. Endocrinology. 1994;135:2386-91. [PubMed ID: 7988421].
- 31.Ahsan F, Arnold J, Meezan E, Pillion DJ. Enhanced bioavailability of calcitonin formulated with alkylglycosides following nasal and ocular administration in rats. Pharm.Res. 2001;18:1742-46. [PubMed ID: 11785695].
- 32.Weber N, Benning H. Metabolism of orally administered alkyl beta-glycosides in the mouse. J. Nutr. 1984;114:247-54. [PubMed ID: 6693987].
- 33.Magio ET. Use of excipients to control aggregation in peptide and protein formulation. J. Excip. Food Chem. 2010;1:40-9.
- 34.Sharma S, Dhanorkar M, Mall P, Tunga R, Tunga B. Stable tween 80 free formulation development for peginterferon alpha 2b. Adv. Biolog. Res. 2011;5:328-38.
- 35.Torosantucci R, Schoneich C, Jiskoot W. Oxidation of therapeutic proteins and peptides: Structural and biological consequences. Pharm. Res. 2014:541-53. [PubMed ID: 24065593].
- 36.Agarkhed M, Dell C, Hsieh M, Zhang J, Goldstein J, Srivastava A. Effect of polysorbate 80 concentration on thermal and photostability of Monoclonal antibody. AAPS. Pharm. Sci. Tech. 2013;14:1-9.
- 37.Fazeli A, Shojaosadati SA, Fazeli MR, Khalifeh K, Ariaeenejad S, Moosavi-Movahedi AA. The role of trehalose for metastable state and functional form of recombinant interferon beta-1b. J. Biotechnol. 2013;163:318-24. [PubMed ID: 23183384].
- 38.Kueltzo LA, Middaugh CR. Ultraviolet absorption spectroscopy. In: Jiskoot W, Crommelin DJA, editors. Methods for Structural Analysis of Protein Pharmaceuticals. 3. Arlington: AAPS; 2005. p. 1-25.
- 39.Kueltzo LA, Middaugh CR. Ultraviolet absorption spectroscopy. Methods for structural analysis of protein pharmaceuticals. Arlington. 2005;3:1-25.
- 40.Aitken A, Learmonth MP. Protein determination by UV absorption. In: Walker JM, editor. The protein protocols handbook. Totowa: Humana Press Inc; 2002. p. 3-6.
- 41.Miranda MC, van Beers, Sauerborn M, Gilli F, Brinks V, Schellekens H, Jiskoot W. Aggregated recombinant human interferon beta induces antibodies but no memory in immune-tolerant transgenic mice. Pharm. Res. 2010;27:1812-24. [PubMed ID: 20499141].
- 42.QI P, Volkin DB, Zhao H, Nedved ML, Hughes R, Bass R, Yi SC, Panek ME, Wang D, Dalmonte P, Bond MD. Characterization of the photodegradation of a human IgG1 monoclonal antibody formulated as a high-concentration liquid dosage form. J. Pharm. Sci. 2009;98:3117-30. [PubMed ID: 19009595].
- 43.Jameel F, Hershanson S. Formulation and process development strategies for manufacturing biopharmaceuticals. John Willey and Sons.Inc; 2010. p. 207-303.
- 44.Karpusas M, Whitty A, Runkel L, Hochman P. The structure of human interferon-β: implications for activity. Cell.Mol. Life. Sci. 1998;54:1203-16. [PubMed ID: 9849615].
- 45.Runkel L, deDios C, Karpusas M, Betzenhauser M, Muldowney C, Zafari M, Benjamin CD, Miller S, Hochman PS, Whitty A. Systematic mutational mapping of sites on human interferon-beta-1a that are important for receptor binding and functional activity. Biochem. 2000;39:2538-51. [PubMed ID: 10704203].
- 46.Karpusas M, Nolte M, Benton CB, Meier W, Lipscomb WN, Goelz S. The crystal structure of human interferon-beta at 2.2-Å resolution. Proc. Natl. Acad. Sci. USA. 1997;94:11813-8. [PubMed ID: 9342320].
- 47.Li S, Nguyen TH, Schöneich C, Borchardt RT. Aggregation and precipitation of human relaxin induced by metal-catalyzed oxidation. Biochem. 1995;34:5762-72. [PubMed ID: 7727437].
- 48.Qiu W, Li T, Zhang L, Yang Y, Kao YT, Wang L, Zhong D. Ultrafast quenching of tryptophan fluorescence in proteins: interresidue and intrahelical electron transfer. Chem. Phys. 2008;350:154-64.
- 49.Chen Y, Barkley MD. Toward understanding tryptophan fluorescence in proteins. Biochem. 1998;37:9976-82. [PubMed ID: 9665702].
- 50.Chio SH, Choi K, Kwon IC, Ahn HJ. The incorporation of GALA peptide into a protein cage for an acid-inducible molecular switch. Biomaterials. 2010;31:5191-8. [PubMed ID: 20359742].
Copyright
©2017 by School of Pharmacy, Shaheed Beheshti University of Medical Sciences and Health Services. This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Similar Articles
Study on the Effect of Solution Conditions on Heat Induced-Aggregation of Human Alpha Interferon
Salmannejad F, Nafissi-Varcheh N, Shafaati A, Aboofazeli R. Study on the Effect of Solution Conditions on Heat Induced-Aggregation of Human Alpha Interferon. Iran J Pharm Res. 2014;13(Suppl):e125472. doi: https://doi.org/10.22037/ijpr.2014.1455
Preparation and Characterization of HP-β-Cyclodextrin-Integrated Chitosan Nanoparticles for Non-invasive Insulin Delivery
Rajabiyan A, Keshavarz M, Zarei-Ahmady A, Shakiba Maram G. Preparation and Characterization of HP-β-Cyclodextrin-Integrated Chitosan Nanoparticles for Non-invasive Insulin Delivery. Jundishapur J Nat Pharm Prod. 2026;21(1):e167615. doi: https://doi.org/10.5812/jjnpp-167615
Preparation and Characterization of Nanoparticle β-Cyclodextrin:Geraniol Inclusion Complexes
Hadian Z, Maleki M, Abdi K, Atyabi F, Mohammadi A, et al. Preparation and Characterization of Nanoparticle β-Cyclodextrin:Geraniol Inclusion Complexes. Iran J Pharm Res. 2018;17(1):e124773. doi: https://doi.org/10.22037/ijpr.2018.2153
Development and Characterization of Paracetamol Complexes with Hydroxypropyl-β-Cyclodextrin
Talegaonkar S, Khan AY, Khar RK, Ahmad FJ, Khan ZI. Development and Characterization of Paracetamol Complexes with Hydroxypropyl-β-Cyclodextrin. Iran J Pharm Res. 2022;6(2):e128316. doi: https://doi.org/10.22037/ijpr.2010.705
Preparation, Physicochemical Characterization and In-vitro Dissolution Studies of Diosmin-cyclodextrin Inclusion Complexes
Ai F, Ma Y, Wang J, Li Y. Preparation, Physicochemical Characterization and In-vitro Dissolution Studies of Diosmin-cyclodextrin Inclusion Complexes. Iran J Pharm Res. 2014;13(4):e125593. doi: https://doi.org/10.22037/ijpr.2014.1561
- Scopus by DOI: 0
Last Update: 3 weeks ago
- Scopus by Title: 12
Last Update: 3 weeks ago
- Scopus by Title (Ref): 14
Last Update: 3 weeks ago
- CrossRef: 1
Last Update: 6 days ago




